FOR IMMEDIATE RELEASE:

AMERICAN BIO MEDICA CHAIRMAN & CEO ROBERT L. AROMANDO JR. INTERVIEWED BY CEOCAST.COM

KINDERHOOK, NY -- March 21, 2024 -- American Bio Medica Corp. (NASDAQ: ABMC) Chairman and CEO Robert L. Aromando Jr. was interviewed yesterday on CEOcast.com (http://www.ceocast.com), the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies.

In the interview, Aromando outlined ABMC's new strategies and directions for it's restructured sales organization. He discussed ABMC goals of capturing greater market share and achieving break-even to profitable levels within the current quarter. Aromando also discussed the Company's plans for future growth, which may involve the development of additional diagnostic products outside of the realm of drugs of abuse, as well as opportunities for the Company to perform contract manufacturing services for other diagnostic companies.

Those interested, may access the interview via the internet at www.ceocast.com.

About CEOcast.com

CEOcast is the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies. Organized by industry, its analysts average over 15 years experience covering and evaluating Wall Street's leading companies. CEOcast's programming is distributed to millions of on-line investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions.

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. ABMC's Drug Detector™ identifies minute traces of illegal drugs on surfaces, while the company's Rapid Drug Screen™ tests individuals and is proven to correlate greater than 99% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Contact:
     American Bio Medica Corp., Kinderhook
     Melissa A. Decker
     Manager Investor Relations
     & Corporate Communications
     Email: melissa@americanbiomedica.com
     Tel: (800) 227-1243
     Fax: (518) 758-8171
     Web: www.americanbiomedica.com